CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

Buy CJC-1295 No DAC – Modified GRF 1-29

Buy CJC-1295 No DAC, also known as Modified GRF (1-29), is a refined synthetic peptide developed to replicate the core activity of growth hormone-releasing hormone (GHRH). Engineered with targeted amino acid substitutions, this version is designed to improve stability while maintaining a shorter, more controlled activity profile compared to DAC-modified variants.

Unlike extended-release versions, CJC-1295 without DAC is often preferred in research settings where precision, timing, and pulsatile growth hormone signaling are key variables.

Key Features Before You Buy CJC-1295 No DAC

• Synthetic GHRH analog (29 amino acids)
• Enhanced stability through targeted substitutions
• Shorter half-life for controlled research applications
• Supports GH and IGF-1 pathway investigations

Chemical Profile

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3367.9 g/mol
• Other Names: Modified GRF (1-29), CJC-1295 No DAC

Mechanism of Action

CJC-1295 (No DAC) is believed to bind to GHRH receptors located on pituitary somatotroph cells. This interaction may activate intracellular signaling pathways involving:

• cAMP production
• Protein kinase activation
• Gene transcription linked to growth hormone release

This cascade may ultimately support the release of growth hormone in a more natural, pulsatile pattern, closely resembling endogenous signaling.

Research Highlights

Growth Hormone & IGF-1 Activity

Studies suggest Modified GRF (1-29) may:

• Increase mean growth hormone output by up to 70–100%
• Elevate IGF-1 levels (~25–30%)
• Support anabolic signaling in experimental models

These pathways are central to research involving tissue growth, repair, and metabolic function.

Muscle & Skin Research

Experimental findings indicate potential links to:

• Lean tissue development
• Increased collagen activity in skin cells
• Fibroblast stimulation and tissue regeneration

Cardiovascular & Recovery Studies

Preliminary research suggests GHRH analogs may:

• Support cardiac tissue response post-injury
• Influence heart function and circulation markers

Synergistic Research Potential

CJC-1295 Peptide for Sale here is frequently studied alongside growth hormone secretagogues such as Ipamorelin.

This dual-pathway approach may:

• Activate both GHRH and ghrelin receptors
• Enhance growth hormone signaling amplitude
• Provide a more complete stimulation model

Why Researchers Choose CJC-1295 (No DAC)

• Greater control over timing vs DAC versions
• Well-studied GH pathway interaction
• Ideal for pulsatile hormone research
• Compatible with peptide stacking protocols